# TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant

> **NCT03110952** · PHASE1 · WITHDRAWN · sponsor: **U.S. Army Medical Research and Development Command**

## Conditions studied

- Dengue

## Interventions

- **BIOLOGICAL:** TDENV-PIV
- **BIOLOGICAL:** TDENV-F17
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03110952
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-01
- **Primary completion:** 2017-04
- **Final completion:** 2018-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** lack of materials, not moving forward
- **Last updated:** 2017-04-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110952, "TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03110952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*